Gore PFO closure trial
This article was originally published in The Gray Sheet
Executive Summary
W.L. Gore announces FDA go-ahead May 5 for a 700-patient clinical trial of its Helex septal occluder for patent foramen ovale closure to prevent recurrence of cryptogenic stroke or transient ischemic attack. The REDUCE trial will randomize patients to receive either the Helex with medical management or medical management alone. Gore is recruiting up to 50 trial sites in the U.S. and Nordic countries and will begin enrolling patients this summer. The firm says its primary endpoint of freedom from recurrent ischemic stroke, imaging confirmed transient ischemic attack, or death from stroke at two-year follow-up is unique. Other PFO closure devices in trials for stroke include NMT Medical's Starflex and AGA Medical's Amplatzer (1"The Gray Sheet" Dec. 9, 2007, p. 9)
You may also be interested in...
Study Establishes Link Between PFO And Cryptogenic Stroke In Older Patients
A new study shows a correlation between patent foramen ovale (PFO) and cryptogenic strokes in older patients
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.